Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MERIT: A Randomized, Double-blind, Placebo-controlled Study of AXS-05 for Relapse Prevention in Treatment Resistant Depression

Next Previous
X
Search
Trial Profile

MERIT: A Randomized, Double-blind, Placebo-controlled Study of AXS-05 for Relapse Prevention in Treatment Resistant Depression

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupropion/dextromethorphan (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms MERIT
  • Sponsors Axsome Therapeutics

    • Most Recent Events

    • 10 Jun 2022 Results presented at the 175th Annual Meeting of the American Psychiatric Association
    • 01 Jun 2022 According to an Axsome Therapeutics media release, 35 patients from this study rolled over in EOLVE trial for long term study.
    • 09 Aug 2021 Primary endpoint has been met. (Relapse) According to an Axsome Therapeutics media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top